Small vessel vasculitis and dry gangrene secondary to combined CTLA-4 and PD-1 blockade in malignant mesothelioma

Article Oncology

Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database

Takahisa Mikami et al.

Summary: The use of immune checkpoint inhibitors (ICIs) is associated with a higher risk of neurological complications, with dual ICI therapy posing a higher risk. Older age, sex, or metastasis were not significant risk factors for the incidence of neurologic ICI-related AEs. Patients at older age, with certain cancer types, or on dual ICI therapy may be at higher risk of fatal neurologic AEs.

JOURNAL OF NEURO-ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Paul Baas et al.

Summary: Nivolumab plus ipilimumab demonstrated significant improvement in overall survival compared to standard chemotherapy for unresectable malignant pleural mesothelioma. This first-in-class treatment regimen has been approved for previously untreated patients in the USA and showed promising outcomes with manageable adverse events.

LANCET (2021)

添加到收藏夹

Article Oncology

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

Dean A. Fennell et al.

Summary: The study evaluated the efficacy and safety of nivolumab in patients with pleural or peritoneal malignant mesothelioma who had progressed following platinum-based chemotherapy. Nivolumab showed improved progression-free survival and overall survival compared to placebo in these patients, with manageable treatment-related adverse events. The results suggest that nivolumab might be a beneficial treatment for patients with malignant mesothelioma who have progressed on first-line therapy.

LANCET ONCOLOGY (2021)

添加到收藏夹

Review Oncology